Company Profile
Grey Wolf Therapeutics Limited
10989365•Private Limited With Share Capital
Get Full Access
29/09/2017
8 years
12
19
72110
very low risk
Company Overview
Registration, classification & business activity
Grey Wolf Therapeutics Limited (10989365) is a private limited with share capital incorporated on 29/09/2017 (8 years old) and registered in abingdon, OX144RY. The company operates under SIC code 72110 - research and experimental development on biotechnology.
Grey wolf therapeutics is a uk-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals tom mccarthy (executive chairman), former president and ceo of spinifex pharmaceuticals and peter joyce (ceo), formerly of vertex pharmaceuticals. ra...
Financial Overview
£28.90M
£2.61M
£26.29M
£20.42M
Key Metrics
19
Employees
12
Directors
66
Shareholders
1
PSCs
30
Patents
Board of Directors
Innovate Grants
This company received a grant of £533438.0 for Accelerating And Expanding The Therapeutic Potential Of Erap1 Inhibition In Cancer. The project started on 01/03/2021 and ended on 31/08/2022.
This company received a grant of £498556.8 for Grey Wolf Therapeutics: Advancing Next-Generation Immunotherapies Through Targeting Of Novel Cancer-Associated Antigens Induced By A First-In-Class Erap1 Inhibitor For The Treatment Of Colorectal Cancer.. The project started on 01/08/2024 and ended on 30/11/2025.
Import / Export
Risk Assessment
very low risk
International Score
Future Factor
excellent
Performance Rating